Claritin patent extension
Executive Summary
Sen. Burns (R-Mont.) withdraws sponsorship from the "Patent Term Restoration Act" (S 1172) that would grant patent extensions to seven "pipeline" drugs including Schering-Plough's Claritin, citing the need for access to generic alternatives "especially for the elderly with limited incomes." The bill retains nine cosponsors, including three members of the Senate Judiciary Committee